On Thursday, Eli Lilly And Co (LLY) stock saw a decline, ending the day at $909.32 which represents a decrease of $-15.24 or -1.65% from the prior close of $924.56. The stock opened at $920.26 and ...

Eli Lilly's innovative culture and strong financial commitment to developing the next generation of drugs set the company apart from its peers and fuel its long-term growth. Lilly holds ...

Developed by Karuna Therapeutics, which was subsequently acquired by Bristol Myers Squibb, the drug works in an entirely ...

WW International Inc. ousted Chief Executive Officer Sima Sistani after a tumultuous two-and-a-half year tenure at the diet ...

As the global population ages, the demand for healthcare services surges, making the sector a promising avenue for long-term ...

Sen. Bernie Sanders’ aggressive targeting of Danish drugmaker Novo Nordisk’s Ozempic and Wegovy pricing, and not Eli Lilly’s ...

Sima Sistani, CEO of WeightWatchers, announced her departure from the weight-loss company, which has struggled to adapt in ...

The success of Eli Lilly’s Zepbound, a challenger to Novo’s Wegovy, has prompted comparisons to a similar scenario, when ...

Jefferies analyst Akash Tewari maintained a Buy rating on Pfizer (PFE – Research Report) today and set a price target of $33.00. The ...

Thousands of plaintiffs have sued Ozempic manufacturers for failing to warn them about the risk of stomach paralysis.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

A woman from Chester Springs, Pennsylvania, is one of the first patients in the country to receive a new FDA-approved ...